Moderna (NASDAQ:MRNA) Cut to Equal Weight at Barclays
Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...
Hosted on MSN14h
Why Moderna (MRNA) Stock Is Up Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 ...
Investors Purchase Large Volume of Call Options on Moderna (NASDAQ:MRNA)
Moderna, Inc. (NASDAQ:MRNA – Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock investors bought 179,268 call options on the company. This represents an increase ...
Moderna, Inc. (NASDAQ:MRNA) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 14, 2025 Moderna, Inc. misses on earnings expectations. Reported EPS is $-2.91 EPS, ...
Hosted on MSN4d
Moderna’s (NASDAQ:MRNA) Q4 Earnings Results: Revenue In Line With Expectations But Full-Year Sales Guidance Misses Expectations Significantly
Biotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...
Why Moderna, Inc. (MRNA) Is Among the Best Healthcare Stocks To Buy According to Analysts
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal year in vaccine race
CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies and vaccines with a market ...
ca.investing.com on MSN17h
Moderna has limited upside: Barclays
Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...
Bernstein Reaffirms Their Hold Rating on Moderna (MRNA)
Bernstein analyst Courtney Breen maintained a Hold rating on Moderna (MRNA – Research Report) on February 14 and set a price target of $45.00.
Nasdaq4d
10 Health Care Stocks With Whale Alerts In Today's Session
For MRNA (NASDAQ:MRNA), we notice a put option trade that happens to be bullish, expiring in 336 day(s) on January 16, 2026. This event was a transfer of 500 contract(s) at a $20.00 strike.
Nasdaq4d
Moderna (MRNA) Reports Q4 Loss, Tops Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $2.50 per share versus the Zacks Consensus Estimate of a loss of $2.69. This compares to earnings of $0.55 per share a year ago. These figures are ...
Nasdaq5d
Interesting MRNA Put And Call Options For April 4th
Investors in Moderna Inc (Symbol: MRNA) saw new options become available today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRNA ...